The Certified Clinical Research Associate designation is now formally recognized by TransCelerate Biopharma, Inc. as evidence of Good Clinical Practice training.
The Certified Clinical Research Associate (CCRA) designation is now formally recognized by TransCelerate Biopharma, Inc. (www.transceleratebiopharmainc.com) as evidence of Good Clinical Practice (GCP) training.
Clinical research professionals who hold a current CCRA designation may use that designation as evidence of GCP training while working at any of TransCelerate's 19 member companies, freeing them from any potential obligatory and/or redundant GCP training.
TransCelerate member companies include some of the world's largest pharmaceutical and biotechnology companies with research and development (R&D) operations, including Johnson & Johnson, AstraZeneca, Pfizer, Roche, GlaxoSmithKline, and more. TransCelerate launched in 2012 "to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety."
"The CCRA designation shows both my employer and the sites I monitor that I have taken the extra step to be a professional," says Kathryn Kimmel, CCRA, CCRC, Senior Clinical Research Associate at PAREXEL International. "The CCRA designation states I have not only GCP training, but know International Conference on Harmonization and all standards that are needed for good clinical research to be performed at the site level and within my company. It establishes me as someone who has demonstrated the ability to apply this knowledge."
Recognition of the CCRA designation follows TransCelerate's January 2014 recognition of the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) designations as evidence of GCP training. In February 2014, TransCelerate also recognized ACRP GCP training courses as evidence of required GCP training.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.